

BUSINESS: Manufacturing: Botaneco Commissions New Manufacturing Operations



SemBioSys' Division, Botaneco, Commissions Commercial Manufacturing Operations
Calgary-Based Personal Care Supplier Set to Meet Anticipated Product Demand

Calgary, Alberta – September 19, 2007 – With the ability to produce commercial volumes of their revolutionary, naturally sourced personal care and cosmetics base emulsion, Botaneco officially commissioned its commercial manufacturing operations at its new 10,000 square foot, state-of-the-art facility in Calgary today. The facility will serve as the central headquarters for the eco friendly manufacturer, housing a fully integrated, advanced site designed for efficient production, quality control and assurance, and distribution.

Botaneco, a business unit of Calgary-based biotechnology company SemBioSys, will manufacture and market branded lines of high performance, naturally derived base emulsions and delivery systems used in the development of cosmetics, personal care and prescription topical/dermatology products. Botaneco is leveraging SemBioSys' proprietary technology, a first-in-class, all-in-one system for emulsification, skin barrier protection and superior hydration and absorption of nutrient rich moisturizers and emollients as well as enhanced performance of skincare actives.

The advanced facility is highlighted by the Botaneco aqueous process – a proprietary technology that harnesses protein protected emollients without the use of traditional extraction methods that use chemicals and solvents. The first branded product line will be unveiled to the public October 2nd during the Society of Cosmetic Chemists show in Long Beach, California.

Botaneco executives expect that this site will be able to meet anticipated aggressive demand and growth expectations. Botaneco will market, manufacture and supply the new base emulsion and delivery system product to businesses that manufacture and market personal care and over-the-counter dermatology products. The Botaneco line offers a more efficient, high performance yet natural alternative to the use of petroleum, chemical or animal derived ingredients and delivery systems traditionally used in personal care and cosmetics emulsifiers.

Botaneco managing director Nancy Markley, Ph.D., said the new facility opening is a smart move in the right direction for the SemBioSys business unit, as demand from consumers continues to push for innovations in creating genuinely eco-friendly products that perform equal to or better than their synthetic counterparts. "Botaneco stands for innovation, intelligence and smart choices. We are a company that constantly strives to find new and better ways to not only expand our offerings, but more importantly work with our partners to help them expand theirs. This facility will enable us to meet this growing demand with products produced to the highest standard under a rigorous quality control program."

"The commissioning of Botaneco's new headquarters and manufacturing operations is a key milestone in the implementation of SemBioSys' strategy to generate revenue in the short and intermediate term from our non-pharmaceutical products while creating long-term value through the commercialization of our pharmaceutical candidates, insulin and Apo AI," said SemBioSys President and CEO, Andrew Baum. "We believe the superior hydration and improved skincare

protection offered by Botaneco products have the potential to transform the value proposition that its customers can offer personal care consumers.”

Botaneco and SemBioSys will be holding a ribbon cutting ceremony later in the fall, followed by a tour of the facility for partners, VIPs and local and national leaders.

About Botaneco

From development through delivery, Botaneco is a performance based, technologically advanced botanical science organization that manufactures and markets a branded line of products that harness the naturally occurring benefits of protein protected seed oils. Botaneco provides performance, innovation and choice in creating natural, renewable and versatile delivery systems and ingredients used in the development of cosmetics, personal care and prescription topical/dermatology products beneficial to humans and the environment. More information can be accessed at www.botaneco.ca.

About SemBioSys

With headquarters in Calgary, Alberta, SemBioSys Genetics Inc. is a biotechnology company developing protein-based pharmaceuticals for metabolic and cardiovascular diseases. The Company's lead pharmaceutical candidates are recombinant human insulin to serve the rapidly expanding global diabetes market and Apo AI, a next generation cardiovascular drug. In addition to its pharmaceutical products, SemBioSys is developing a series of non-pharmaceutical products addressing animal and aquaculture health, nutritional oils and human topical markets. More information is available and can be accessed at www.sembiosys.com.

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at www.sedar.com. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

For further information contact:

Botaneco
Andrew Baum
President and Chief Executive Officer
Ph: 403-717-8751
Fax: [403-250-3886](tel:403-250-3886)
Email: bauma@sembiosys.com
